2022
Impact of resilience, social support, and personality traits in patients with neuroinflammatory diseases during the COVID-19 pandemic
Jakimovski D, Kavak KS, Longbrake EE, Levit E, Perrone CM, Bar-Or A, Benedict RH, Riley CS, De Jager PL, Venkatesh S, Walker ELS, Xia Z, Weinstock-Guttman B, Collaborative M. Impact of resilience, social support, and personality traits in patients with neuroinflammatory diseases during the COVID-19 pandemic. Multiple Sclerosis And Related Disorders 2022, 68: 104235. PMID: 36283322, PMCID: PMC9548342, DOI: 10.1016/j.msard.2022.104235.Peer-Reviewed Original ResearchWorsening physical functioning in patients with neuroinflammatory disease during the COVID-19 pandemic
Levit E, Cohen I, Dahl M, Edwards K, Weinstock-Guttman B, Ishikawa T, Kavak K, Leavitt V, Nelson K, Onomichi K, Bar-Or A, Perrone C, Riley C, Venkatesh S, De Jager PL, Xia Z, Longbrake EE, Collaborative M. Worsening physical functioning in patients with neuroinflammatory disease during the COVID-19 pandemic. Multiple Sclerosis And Related Disorders 2022, 58: 103482. PMID: 35016114, PMCID: PMC8742609, DOI: 10.1016/j.msard.2021.103482.Peer-Reviewed Original ResearchConceptsPhysical functionDepression scoresCOVID-19 pandemicPhysical disabilityNeurological inflammatory diseasesMajor academic medical centerAcademic medical centerHigher baseline levelsLack of diseaseDisease durationStudy entryTherapy useNeuroinflammatory diseasesMale genderInflammatory diseasesPhysical functioningMedical CenterMood symptomsDepressive symptomsSmall cohortBaseline levelsSerial surveysSignificant depressionOlder ageWorse depression
2021
Vaccination Against SARS-CoV-2 in Neuroinflammatory Disease: Early Safety/Tolerability Data
Epstein S, Xia Z, Lee AJ, Dahl M, Edwards K, Levit E, Longbrake EE, Perrone C, Kavak K, Weinstock-Guttman B, Diallo F, Ricci A, Riley CS, De Jager PL, Farber R, Wesley SF, Collaborative M. Vaccination Against SARS-CoV-2 in Neuroinflammatory Disease: Early Safety/Tolerability Data. Multiple Sclerosis And Related Disorders 2021, 57: 103433. PMID: 34923427, PMCID: PMC8638239, DOI: 10.1016/j.msard.2021.103433.Peer-Reviewed Original ResearchMeSH KeywordsCOVID-19COVID-19 VaccinesCross-Sectional StudiesHumansNeuroinflammatory DiseasesSARS-CoV-2VaccinationConceptsNeuromyelitis optica spectrum disorderSelf-reported side effectsNeuroinflammatory diseasesSARS-CoV-2Multiple sclerosisSide effectsSARS-CoV-2 vaccine trialsCross-sectional observational studySafety/tolerability dataAsymptomatic control populationNeurologist-confirmed diagnosisRadiologic disease activityRecurrent neurologic symptomsSignificant vaccine hesitancyOptica spectrum disorderAntibody-mediated diseasesVaccine side effectsViral vector vaccinesReal-world evidenceMultiple academic centersNID patientsUnvaccinated patientsVaccines surveyDisease activityNeurologic events